1022-86 Association of inflammation and benefit of statins in patients with acute myocardial infarction  by Kinjo, Kunihiro et al.
252A ABSTRACTS - Myocardial Ischemia and Infarction JACC March 3, 2004
M
yo
ca
rd
ia
l I
sc
he
m
ia
 a
nd
 In
fa
rc
tio
n
delay ranged from 7 to 104 minutes, while absolute survival benefit ranged from –4
(favoring Rx) to 15 (favoring PTCA). The survival benefit decreased as the PTCA-related
delay increased (figure). After the exclusion of AIR PAMI trial (longest delay and high risk
patients) equivalence of survival rates between PTCA and Rx was reached for a PTCA
related delay of 63 minutes: change in benefit per 10-minutes delay was 1 % (P=0.01). In
clinical trials with short PTCA-related delays, PTCA produced better outcomes, while tri-
als with longer delays favored Rx. At experienced institutions and for high risk patients,
however, PTCA is probably still preferable, even when delay is longer.
1022-85 Glucose-Insulin-Potassium Infusion Improves 
Myocardial Salvage in Diabetic Patients With Acute 
Myocardial Infarction Treated With Reperfusion Therapy
Jürgen Pache, Joerg Hausleiter, Adnan Kastrati, Julinda Mehilli, Hildegard Bolwein, 
Helmut Schühlen, Josef Dirschinger, Albert Schoemig, 1. Medizinische Klinik rechts der 
Isar, Munich, Germany, Deutsches Herzzentrum Muenchen, Munich, Germany
Patients (pts) with acute myocardial infarction (AMI) who receive reperfusion therapy
might have some benefit from glucose-insulin-potassium infusion (GIK). GIK is expected
to enhance myocardial salvage obtained with reperfusion. The objective of this subgroup
analysis of the randomized Reevaluation of Intensified Venous Metabolic Support for
Acute Infarct Size Limitation (REVIVAL) trial was to assess whether GIK improves myo-
cardial salvage in various subsets of pts.
We randomized 312 patients with AMI to receive either GIK infusion for 24 hours (GIK
group, n=155) or no GIK (control group, n=157). The primary endpoint of the study was
salvage index (proportion of myocardium at risk salvaged by therapy) as measured by
technetium Tc 99m sestamibi scintigraphic studies performed before and 7-10 days after
therapy. Various subsets of pts (fig) were analyzed according to their difference in sal-
vage index.
In the overall pts group salvage index was 0.5 in the GIK group and 0.48 in the control
group (p=0.96). The subgroup analysis is shown in the figure.
The results of this subgroup analysis demonstrate that GIK enhance myocardial salvage
only in pts with diabetes. 
1022-86 Association of Inflammation and Benefit of Statins in 
Patients With Acute Myocardial Infarction
Kunihiro Kinjo, Hiroshi Sato, Yozo Ohnishi, Eiji Hishida, Daisaku Nakatani, Hiroya 
Mizuno, Masahiko Shimizu, Masatsugu Hori, Osaka University Graduate School of 
Medicine, Suita, Japan
Background _ Inflammation as detected by elevated C-reactive protein (CRP) levels
predicts the risk of coronary events. The effect of inflammation on coronary risk has
shown to be attenuated by statin therapy in patients with stable coronary artery disease.
However, this effect of statin therapy for acute myocardial infarction (AMI) is unknown.
Methods and Results _ We studied 3508 survived AMI patients who enrolled in Osaka
Acute Coronary Insufficiency Study. CRP was measured during the stable phase (mean,
21 days after the onset). Patients with statin treatment at discharge had a lower 1-year
mortality than those without statin treatment (1.1% versus 3.2%, log rank, p<0.001). Mul-
tivariate Cox regression analysis revealed that statin treatment remained predictive of a
lower 1-year mortality rate (hazard ratio (HR), 0.38; 95% confidence interval (CI), 0.15-
0.96). Although the 1-year mortality was not different among patients with and without
statin treatment in patients with low CRP, the 1-year mortality was higher in the patients
without statin treatment than in those with statin treatment in patients with high CRP. In
the presence of statin therapy, the HR for 1-year mortality was significantly reduced in
patients with high CRP (HR, 1.46, 95% CI, 0.15-14.5) to about the same degree as in
patients with low CRP and who did not receive statin therapy (HR, 2.53; 95% CI, 0.46-
13.8).
Conclusions _ Statin treatment at discharge is associated with reduced 1-year mortality
of patients with AMI. Furthermore, statin treatment significantly attenuates the increased
risk for 1-year mortality in patients with AMI. Measurement of CRP levels may improve
targeting of statin therapy in patients with AMI.
1022-87 Improvement of Long-Term Outcome in Acute 
Myocardial Infarction Over Time: Experiences From the 
Register of Information and Knowledge About Swedish 
Heart Intensive Care Admissions
Ulf Stenestrand, Lars Wallentin, Heart Center, University Hospital, Linkoping, Sweden, 
UCR, University Hospital, Uppsala, Sweden
Background: During the last years several new therapies, some very costly, have proven
in clinical trials to improve survival in patients with acute myocardial infarction (AMI). The
aim of this study was to evaluate if these new therapies have changed long term outcome
in a non selected CCU population of daily care patients.
Methods & Results: All patients admitted to participating CCUs were included. Clinical
background, admission status, medications, interventions, complications were recorded
for the years 1995-2001 including 1 year follow-up until the end of 2002 in 90% of the
Swedish hospitals. Among the CCU patients there were 73828 with AMI. In hospital and
long term mortality decreased for each studied year. The Kaplan-Meier curves indicate
that during the study period 1-year mortality has sunken from 21% to 16% in patients 66-
75 years (figure 1), 9% to 6% in patients below 65 years, and 39% to 35% in patients
older than 75 years.
Conclusion: This analysis supports that new therapies have helped to improve 1-year
survival in not only in selected trial patients but also in an unselected cohort of daily CCU
patients of all ages with AMI.
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1023-89 Chelation Therapy for Patients With Coronary Heart 
Disease: Findings From the Pilot to Assess Chelation 
Therapy
Gervasio A. Lamas, Alan Ackermann, Danielle Hollar, Paul Kurlansky, Joseph Vita, 
Charles H. Hennekens, Mount Sinai Medical Center-Miami Heart Institute, Miami Beach, 
FL, Boston University School of Medicine, Boston, MA
Background: Chelation therapy involves a series of intravenous infusions of dsodium
EDTA. Despite widespread use for the treatment of coronary heart disease (CHD), ran-
domized data on safety and benefits are relatively sparse. The Pilot for the Trial to Assess
Chelation Therapy (PACT) was a randomized, double-blind, placebo-controlled trial, com-
paring EDTA chelation with placebo infusions.
Methods: PACT randomized and followed 40 patients, 30 assigned to chelation therapy
infusions, and 10 to placebo infusions. All patients received 15 weekly infusions of chela-
tion or normal saline, plus low-dose vitamin supplementation. Laboratory safety data
were compared between groups on the last day of infusion. We also performed
endothelial function studies using brachial artery flow-mediated dilation expressed as
percent above baseline (FMD %).
Results: On the day of the last infusion, there were no significant differences between
the chelation and placebo groups for: creatinine (1.1 v 1.1), glucose (112 v 134), hemat-
